Growth factor receptor interplay and resistance in cancer

Jones, Helen E., Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015, Hutcheson, Iain Robert, Knowlden, Janice Mary, Barrow, Denise and Nicholson, Robert Ian 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13 (S1) , S45-S51. 10.1677/erc.1.01275

Full text not available from this repository.

Abstract

Aberrant signalling through the epidermal growth factor receptor (EGFR) plays a major role in the progression and maintenance of the malignant phenotype and the receptor is therefore a rational anti-cancer target. A variety of approaches have been developed to specifically target the EGFR which include monoclonal antibodies and small molecule tyrosine kinase inhibitors, such as gefitinib (Iressa). However, the recent clinical experience across a range of cancer types is revealing that despite the anti-EGFR agents demonstrating some anti-tumour activity, there is a high level of de novo and acquired resistance to such treatments and moreover, overexpression of the EGFR is clearly not the sole determinant of response to such therapies. Such adverse phenomena, which serve to limit the overall therapeutic impact of these new agents, implies the existence of a greater complexity involved in the regulation of EGFR signalling than was previously assumed. Indeed, evidence is accumulating which demonstrates that signalling interplay occurs between the EGFR, and the IGF-1 receptor (IGF-1R) and the review will focus on the emerging concept of growth factor pathway switching between these two receptors as a means of influencing the effectiveness of anti-EGFR agents such as gefitinib.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Medicine Biosciences
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Additional Information:	This paper was presented at the 2nd Tenovus/AstraZeneca Workshop, Cardiff (2006). AstraZeneca supported the meeting and the Welsh School of Pharmacy, Cardiff University has supported the publication of these proceedings.
Publisher:	Society for Endocrinology
ISSN:	1351-0088
Last Modified:	18 Oct 2022 14:21
URI:	https://orca.cardiff.ac.uk/id/eprint/17213

Citation Data

Cited 69 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item